Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Asciminib Roll-over Study
NCT04877522 · View on ClinicalTrials.gov ↗
Study Summary
This is a long term safety study for patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment
Conditions Studied
Interventions
- DRUG Dasatinib
- DRUG Bosutinib
- DRUG Nilotinib
- DRUG Asciminib single agent
- DRUG Imatinib
Study Locations (20)
Other
- Novartis Investigative Site — Capital Federal
- Novartis Investigative Site — Graz
- Novartis Investigative Site — Vienna
- Novartis Investigative Site — Varna
Texas
- Texas Oncology — Dallas
- Uni Of TX MD Anderson Cancer Cntr — Houston
São Paulo
- Novartis Investigative Site — São Paulo
- Novartis Investigative Site — São Paulo
Michigan
- Michigan Med University of Michigan — Ann Arbor
New York
- Memorial Sloan Kettering — New York
Oregon
- Oregon Health Sciences University — Portland
Buenos Aires
- Novartis Investigative Site — CABA
Rio de Janeiro
- Novartis Investigative Site — Rio de Janeiro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 347 participants |
| Start Date | 2022-08-30 |
| Est. Completion | 2030-08-30 |
| Phase | Phase 4 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04877522
The ClinicalTrials.gov registry entry for NCT04877522 describes a study currently listed as recruiting. It is categorized as Phase 4, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 347 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 792 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Chronic Myelogenous Leukemia appearing as the primary indexed condition, and to 5 interventions — of which Dasatinib is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04877522 reports 20 study locations spanning 15 distinct geographic areas — top geographies include Other, Texas, São Paulo. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04877522 about?
NCT04877522 is a clinical study titled "Asciminib Roll-over Study". This is a long term safety study for patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment
What is the current status of trial NCT04877522?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 347 participants. The study started on 2022-08-30. Estimated completion is 2030-08-30.
What conditions does trial NCT04877522 study?
This clinical trial studies the following conditions: Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04877522?
The interventions under investigation include: Dasatinib (DRUG), Bosutinib (DRUG), Nilotinib (DRUG), Asciminib single agent (DRUG), Imatinib (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04877522?
This trial is sponsored by Novartis Pharmaceuticals, which has 792 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04877522 being conducted?
This trial has 20 study locations across Michigan, New York, Oregon, Texas, Buenos Aires. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.